Bioarray Genetics to Present at the 2019 International Cancer Cluster Showcase on June 3rd

16-May-2019
For Immediate Release

Bioarray Genetics, Inc. announced today that it was selected to present at the 2019 International Cancer Cluster Showcase as part of its North American and European cutting-edge oncology innovations group. Bioarray is scheduled to present on Monday, June 3rd at the Pennsylvania Convention Center in Philadelphia, PA.

About the International Cancer Cluster Showcase

Scheduled at the beginning of BIO 2019, the International Cancer Cluster Showcase (ICCS) is attended by participants wanting to hear more about emerging start-ups, novel licensing opportunities, promising clinical trial results, and innovative technology platforms. Companies are selected to present based on a review of their technology, patient care impact, and market relevance by a panel of oncology business leaders and investors.

More information about ICCS can be found at: http://www.internationalcancercluster.org/

About Bioarray Genetics, Inc.

Bioarray Genetics is developing the world’s first stratification test (BA100) for Triple Negative Breast Cancer (TNBC), which affects nearly 20% of breast cancer patients and has the lowest overall response and survival rates. BA100 will inform Oncologists if their patient will achieve a pathological complete response (pCR) to the standard-of-care neoadjuvant chemotherapy. By combining the BA100 Stratification Test with on-market complementary diagnostics such as BRCA1/2 mutations and PD-L1 expression, an Oncologist can decide which treatment is best for their patient at the time of diagnosis. Bioarray is currently considering strategic commercial partners for the TNBC total care approach, which combines results of genomic profiling by BA100 with BRCA1/2 and PD-L1 in a comprehensive TNBC Total Care Report. Bioarray utilizes its growing database of clinical, genomic, and transcriptome data to develop life-changing algorithms to solve areas of unmet medical need and empowering treatment decisions.

Bioarray Genetics is part of the UConn technology incubation program (TIP) located in Farmington, Connecticut. Utilizing UConn's TIP program, Bioarray has access to world-class research, resources, facilities, and business support services as well as experienced investors and entrepreneurs.

More information about Bioarray can be found at: https://bioarray.us/
For more information, please contact:
Chris Moore
Bioarray Commercial Head
cmoore@bioarray.us